[Pirprofen, indomethacin and placebo in ankylosing spondylitis. Double-blind comparison].
One hundred and four patients with ankylosing spondylitis were involved in a comparative trial carried out in one single centre. They were given either pirprofene (1000 mg/day), indomethacin (125 mg/day) or a placebo for 6 consecutive weeks. Response to treatment was assessed after 1, 2, 4 and 6 weeks on the basis of 4 subjective criteria and 6 standard measurements. The overall therapeutic results were judged by the investigator to be satisfactory in 87% of patients in the pirprofene group, 77% in the indomethacin group and 29% in the placebo group (p less than 0.01). A large number of patients in each group (including 34% on placebo) reported side effects. Treatment was discontinued on account of gastric pain in two patients (one on pirprofen, the other on indomethacin). No abnormalities were detected in laboratory tests.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010666:Phenylpropionates / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D010666:Phenylpropionates; D010919:Placebos; C008924:pirprofen; D007213:Indomethacin
Pirprofène, indométacine et placebo dans la spondylarthrite ankylosante. Comparaison en double insu.